NCT07650916招募中3 期
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 564
- 试验地点
- 88
- 主要终点
- Percentage of participants with plasma HIV-RNA greater than or equal to (>=) 50 copies (c)/mL as per Food and Drug Administration (FDA) Snapshot algorithm
研究概览
简要总结
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This is an open-label study.
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient Study Participant (PSP) Inclusion criteria:
- •Adults and adolescents with HIV-1 infection aged 12 years or older with a weight >35 kg.
- •Documented HIV-1 RNA measurements <50 copies/mL in the 12 months prior to Screening.
- •HIV-1 RNA <50 copies/mL at screening assessment.
- •Must be on current daily oral antiretroviral regimen for at least 6 months uninterrupted prior to Screening.
- •Any prior switch in therapy must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for virologic treatment failure (HIV-1 RNA ≥200 copies/mL).
排除标准
- •Patient Study Participant (PSP) Exclusion criteria:
- •Any evidence of primary resistance based on the presence of any major known INSTI (including CAB) or NNRTI (including RPV) resistance-associated mutation.
- •Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening.
- •Any history of receiving long-acting therapy for HIV.
- •Previous exposure to CAB and/or RPV for treatment or prevention of HIV-1 infection.
- •Significant uncontrolled or clinically relevant comorbidities (e.g., cardiovascular, hepatic, renal, neurological, psychiatric) that may impact safety or study participation.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
CAB LA+ RPV LA
Active Comparator
Participants will receive CAB LA+RPV LA.
干预措施: CAB LA (Drug)
CAB LA+ RPV LA
Active Comparator
Participants will receive CAB LA+RPV LA.
干预措施: RPV LA (Drug)
CAB ULA+ RPV ULA
Experimental
Participants will receive CAB ULA+RPV ULA.
干预措施: CAB ULA (Drug)
CAB ULA+ RPV ULA
Experimental
Participants will receive CAB ULA+RPV ULA.
干预措施: RPV ULA (Drug)
结局指标
主要结局
Percentage of participants with plasma HIV-RNA greater than or equal to (>=) 50 copies (c)/mL as per Food and Drug Administration (FDA) Snapshot algorithm
时间窗: At Month 11
次要结局
- Percentage of participants with plasma HIV-RNA >= 50 c/mL as per FDA Snapshot algorithm(At Month 23)
- Percentage of participants with plasma HIV-RNA less than (<) 50 c/mL as per FDA Snapshot algorithm(At Month 11 and Month 23)
- Percentage of participants with confirmed virologic failure (CVF)(Up to Month 23)
- Number of participants with drug-related adverse events (AEs) as per severity of Grade 2-5(Up to Month 23)
- Number of participants with drug-related serious adverse events (SAEs)(Up to Month 23)
- Number of participants who discontinue treatment due to AEs or injection intolerability(Up to Month 23)
- Number of participants with treatment emergent genotypic or phenotypic resistance to CAB and RPV(Up to Month 23)
- Ctrough of CAB and RPV(Up to Month 23)
- Maximum concentrations post dose (Cmax) of CAB and RPV(Up to Month 23)
- Area under the curve (AUC) of CAB and RPV(Up to Month 23)
- Absolute value of CD4+ cell counts in participants(Up to Month 23)
- Change from Baseline in CD4+ cell counts in participants(At Month 23 compared to baseline (Day 1))
研究者
研究点 (88)
Loading locations...
相似试验
招募中
不适用
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative ColitisNCT07442045Sixth Affiliated Hospital, Sun Yat-sen University150
已完成
不适用
Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without DiabetesHypercholesterolemiaNCT07382778JW Pharmaceutical1,538
招募中
1 期
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus ErythematosusNCT07444307Hangzhou Qihan Biotech Co., Ltd.18
已完成
2 期
To evaluate the Efficacy and Safety of study product i.e., LYCO3 in Male Subjects who Suffering from Erectile DysfunctionCTRI/2024/07/071171Nutragen Pharma Pvt. Ltd.20
尚未招募
4 期
Lupin Dental smile designing India StudyCTRI/2025/10/095662Lupin Dental45